SCHEMBL265678

SCHEMBL265678

CN(CCCNCc1ccc(C(=O)Nc2ccc(Br)cc2C(=O)NN=Cc2ccc(F)cc2)cc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.45
MEN1 O00255 7/20 0.45
NPC1 O15118 7/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
POLB P06746 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPT P10636 8/20 0.45
ALDH1A1 P00352 5/20 0.45
RAB9A P51151 8/20 0.42
KDM4E B2RXH2 2/20 0.42
PKM P14618 3/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.40
HPGD P15428 2/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265677 1.00 KMT2A (0.45) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL268112 0.93 RAB9A (0.42) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL268113 0.93 RAB9A (0.42) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL268175 0.93 SLC34A2 (0.42) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL268174 0.93 SLC34A2 (0.42) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL268813 0.91 HPGD (0.51) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL268812 0.91 HPGD (0.51) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL266146 0.91 MAPT (0.39) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL266145 0.91 MAPT (0.39) KMT2AMEN1NPC1SMN1; SMN2POLB
SCHEMBL273943 0.88 SLC34A2 (0.37) KMT2AMEN1NPC1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KMT2A 4564/4885MEN1 1194/4885NPC1 102/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KMT2A 4603/4885MEN1 1638/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.